---
title: CDMO Daily News — July 17, 2026
slug: daily-news-2026-07-17-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: July 17 CDMO daily: BriaCell Selects FUJIFILM Biotechnologies California for Bria-IMT Phase 3 and Commercial Manufacturing; OXB Secures AAV Manufacturing…
canonical_url: https://cdmo.directory/posts/daily-news-2026-07-17-cdmo
published_at: 2026-07-17T13:00:16.165Z
last_updated: 2026-07-17T13:58:07.713Z
---

### BriaCell Selects [FUJIFILM Biotechnologies](/companies/fujifilmdiosynth) California for Bria-IMT Phase 3 and Commercial Manufacturing
- BriaCell Therapeutics has contracted [FUJIFILM Biotechnologies](/companies/fujifilmdiosynth) California for CDMO services supporting Phase 3 clinical development and potential commercial supply of Bria-IMT, an off-the-shelf allogeneic cell therapy.
- Bria-IMT is in a pivotal Phase 3 trial (NCT06072612) for advanced metastatic breast cancer in combination with an immune checkpoint inhibitor.

**Operational Impact**

[FUJIFILM Biotechnologies](/companies/fujifilmdiosynth) California adds cell therapy manufacturing capacity for a pivotal Phase 3 program with potential commercial scale-up, expanding its allogeneic cell therapy CDMO footprint.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/briacell-therapeutics-partners-with-fujifilm-biotechnologies-california-for-phase-3-bria-imt-manufacturing)*

---

### [OXB](/companies/oxb) Secures AAV Manufacturing Contract with Plowshare Therapies
- [OXB](/companies/oxb) will provide process development and AAV GMP manufacturing services to Plowshare Therapies for rare genetic disease gene therapies.
- Manufacturing will be conducted at OXB's FDA-approved viral vector facility in Durham, North Carolina, with potential for scale-up as Plowshare's pipeline advances.

**Operational Impact**

[OXB](/companies/oxb)'s Durham viral vector facility adds committed AAV GMP capacity for rare disease programs, with contractual optionality for later-stage manufacturing as Plowshare advances its pipeline.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/oxb-signs-aav-manufacturing-deal-with-plowshare-therapies)*

---

### Merck Opens €25M BioReliance Testing Facility in Darmstadt, Germany
- Merck inaugurated a 2,000-square-meter BioReliance testing facility in Darmstadt offering GMP-compliant drug substance, drug product release, and stability testing for biologics and cell therapies.
- The €25 million investment expands European in-region testing capacity and positions the site near major clinical trial hubs across Germany, France, Spain, Netherlands, Belgium, and Italy.
- Headcount is projected to grow significantly over coming years; the facility complements Merck's 2024 €290 million biosafety testing facility opened in Rockville, Maryland.

**Operational Impact**

The Darmstadt facility reduces testing turnaround for European biopharmaceutical clients by eliminating transatlantic sample shipment delays and regulatory complexity, strengthening Merck's competitive position in EMEA drug-product release and stability testing.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/merck-opens-e25-million-bioreliance-testing-facility-in-darmstadt-germany)*

---

### [Cytovance Biologics](/companies/cytovance-biologics) Adds Perfusion Capabilities to Upstream Process Development
- [Cytovance Biologics](/companies/cytovance-biologics) has integrated perfusion technology into its upstream process development platform, complementing existing fed-batch manufacturing services.
- Perfusion enables continuous media supply and spent-media removal, supporting higher productivity and longer cell culture durations for monoclonal antibodies and recombinant proteins.
- The capability expands Cytovance's integrated CDMO offering alongside recent additions in cell line development and formulation services.

**Operational Impact**

[Cytovance Biologics](/companies/cytovance-biologics)’ perfusion integration expands upstream flexibility for sponsors evaluating process strategies, reducing time-to-clinic for programs where fed-batch alone may not meet productivity or culture-duration requirements.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cytovance-biologics-expands-upstream-process-development-with-perfusion-capabilities)*

## References

1. [PharmaSource RSS — BriaCell Selects FUJIFILM Biotechnologies California for Bria-IMT Phase 3 and Commercial Manufacturin](https://pharmasource.global/content/news/cdmo-news/briacell-therapeutics-partners-with-fujifilm-biotechnologies-california-for-phase-3-bria-imt-manufacturing)
2. [Contract Pharma Breaking News RSS — OXB Secures AAV Manufacturing Contract with Plowshare Therapies](https://www.contractpharma.com/breaking-news/oxb-signs-aav-manufacturing-deal-with-plowshare-therapies)
3. [Contract Pharma Breaking News RSS — Merck Opens €25M BioReliance Testing Facility in Darmstadt, Germany](https://www.contractpharma.com/breaking-news/merck-opens-e25-million-bioreliance-testing-facility-in-darmstadt-germany)
4. [PharmaSource RSS — Cytovance Biologics Adds Perfusion Capabilities to Upstream Process Development](https://pharmasource.global/content/news/cdmo-news/cytovance-biologics-expands-upstream-process-development-with-perfusion-capabilities)

Source: https://cdmo.directory/posts/daily-news-2026-07-17-cdmo